- AHPBA/SSO/SSAT Sponsored Consensus Conference on Multidisciplinary Treatment of Hepatocellular Carcinoma » June 2010
- Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution.
The largest published series of hepatic resections for metastatic colorectal cancer to date.
- Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings.
One of the first publications describing the technique now referred to as Associating Liver and Portal Vein Ligation for Staged Hepatectomy (ALPPS).
- Comparative benefits of laparoscopic vs open hepatic resection: a critical appraisal.
Retrospective analysis of large single-institution series as well as literature review of case-cohort matched studies of minimally invasive vs open liver resection.
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
A follow-up study to the seminal RCT published in NEJM in 2008 demonstrating improved survival with sorafenib in advanced HCC.
- High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome.
Large retrospective cohort study demonstrating better survival with two-stage hepatectomy strategy than with chemotherapy alone for colorectal liver metastases.
- Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. 2013
RCT demonstrating improved survival with TACE + RFA over RFA alone.
- Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
A follow-up study to the seminal RCT published in Lancet in 2008 demonstrating improved progression-free survival (but not overall survival) for perioperative chemotherapy.